According to GLOBOCAN 2018, prostate cancer is the second most common malignancy and the fifth leading cause of cancer death in men worldwide.

In Canada, prostate cancer is the most common cancer among Canadian men (excluding non-melanoma skin cancers).

24,600 Canadian men will be diagnosed with prostate cancer. This represents 20% of all new cancer cases in men in 2022. On average, 67 Canadian men are diagnosed with prostate cancer every day.


It is the third leading cause of death from cancer among men in Canada.

4,600 Canadian men are expected to die from prostate cancer. This represents 10% of all cancer deaths in men in 2022.

On average, 13 Canadian men die from prostate cancer every day.

Today we are discussing the precision medicine controversy concerning patient optimization and selection in mCRPC with HRR mutation gene following progression on androgen deprivation therapy (ADT).

Incorporating PARP inhibitors into routine prostate cancer management in patients with limited treatment options is promising.

However, some factors to consider in Choosing the Right Patient, concerning the associated mutated gene, such as BRCA/Non-BRCA.

Thanks so much for your time, and I am looking forward to hearing from you...!

"PharCast" is a podcast interested in exploring and pushing the boundaries of science and medicine, which results in better treatments, a better health system, and better health for everyone. It explores both emerging trends in pharmacy and ground-breaking science.